Clinical Trials on Endometrial Safety in Ireland

Total 117 results

Calithera Biosciences, Inc

Completed

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

Cardiac Safety

United Kingdom
John Laffey

Completed

Observational Study of Baska Mask, a New Supraglottic Airway Device in Children

Baska Mask Efficacy and Safety in Children

Ireland
John Laffey

Completed

A Comparison of the Performance of Standard Double Lumen Tubes With Vivasight DL™ Double Lumen Tubes for Lung Isolation in Patients Undergoing Thoracic Surgery

Performance and Safety of an Airway Management Device

Ireland
University College Hospital Galway

Completed

Observational Study of Baska Mask, a New Supraglottic Airway Device

Performance and Safety of a New Supraglottic Airway Device

Ireland
John Laffey

Completed

Comparison of the Baska Mask Airway to a Single-use LMA Device in Low-risk Female Patients

Performance and Safety of an Airway Management Device

Ireland
University College Hospital Galway

Completed

Comparison of the BASKA Airway, a Novel Supraglottic Device, to the LMA Airway in Low Risk Female Patients

Performance and Safety of an Airway Management Device

Ireland
Royal College of Surgeons, Ireland
The Rotunda Hospital

Completed

Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity

Endometrial Hyperplasia | Endometrial Cancer | Postmenopausal Bleeding

Ireland
Women and Infants Hospital of Rhode Island
Agency for Healthcare Research and Quality (AHRQ)

Unknown

Generalizing TESTPILOT to New Single Family Room NICUs (TESTPILOT)

Patient Safety | Organizational Change

United States
Brandeis University
National Institute on Drug Abuse (NIDA); Oregon Health and Science University; University of Washington and other collaborators

Active, not recruiting

RESPOND TO PREVENT: Stepwise Pharmacy Naloxone Study

Opioid Use | Patient Safety | Pharmacies

United States
University College Cork
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Cork University... and other collaborators

Active, not recruiting

The LYSA (Linking You to Support and Advice) Trial (LYSA)

Cervical Cancer | Breast Cancer | Endometrial Cancer | Survivorship

Ireland
Cancer Trials Ireland

Terminated

Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06

Endometrial Cancer | Radiation Toxicity | Gastrointestinal Complications | Urinary Complications

Ireland
Women and Infants Hospital of Rhode Island

Unknown

The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy

Grade 1 Endometrial Endometrioid Adenocarcinoma | Grade 2 Endometrial Endometrioid Adenocarcinoma | Complex Atypical Endometrial Hyperplasia

United States
Nordic Society of Gynaecological Oncology - Clinical...
European Organisation for Research and Treatment of Cancer - EORTC

Completed

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer

Endometrial Cancer

France, Norway, Belgium, Spain, Netherlands, Italy, United Kingdom, Ireland, Poland, Portugal, South Africa
Lifespan

Completed

Buckle Me Up!: A Digital Emergency Department Discharge Intervention for Child Car Safety

Injuries | Safety Issues | Car Accident

United States
Leiden University Medical Center
Comprehensive Cancer Centre The Netherlands; Dutch Cancer Society

Active, not recruiting

PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer (PORTEC-4a)

Endometrial Cancer Stage I | Endometrial Cancer Stage II

Netherlands, Germany, Belgium, France, Austria, Czechia, Ireland, Switzerland
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Mixed Adenocarcinoma | Stage IIIA Uterine Corpus Cancer | Stage IIIC Uterine Corpus Cancer | Stage... and other conditions

United States
Xoft, Inc.

Completed

Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer

Endometrial Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma | Endometrial...

United States
National Cancer Institute, Naples

Recruiting

Endometrial Cancer Conservative Treatment (E.C.Co). A Multicentre Archive

Endometrial Cancer

United States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Spain, United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Completed

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Recurrent Uterine Corpus Cancer

United States
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
Sanofi

Completed

Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma

Endometrial Neoplasms | Endometrial Cancer

United States, Belgium
University Hospital, Basel, Switzerland

Completed

Validation Study of ClassIntra® (ClassIntra®)

Postoperative Complications | Intraoperative Complications | Patient Safety | Risk Management

New Zealand, Switzerland, United States, Netherlands, Spain, Austria, Turkey, United Kingdom, Australia, Greece, Ireland, Italy
Biotronik, Inc.

Completed

ProMRI Study of the Entovis Pacemaker System

Safety of the ProMRI Pacemaker System Under Specific MRI Conditions

United States
European Organisation for Research and Treatment...

Completed

Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer

Endometrial Cancer

Netherlands, France, Spain, United Kingdom, Belgium, Italy, Austria, Portugal
Aadi Bioscience, Inc.

Recruiting

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Cancer | Endometrial Cancer | Tumor | Recurrent Endometrial Carcinoma | Endometrioid Endometrial Cancer | Endometrioid Tumor

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm

United States
Women and Infants Hospital of Rhode Island
University of Alabama at Birmingham; Hartford Hospital

Unknown

Cancer of the Uterus and Treatment of Stress Urinary Incontinence (CUTI)

Stress Urinary Incontinence | Endometrial Cancer

United States
Artios Pharma Ltd

Recruiting

Study of ART0380 in Patients With Biologically Selected Solid Tumors (ARTIST)

Metastatic Cancer | Advanced Solid Tumor | Recurrent Endometrial Cancer

United States, France
McGill University

Recruiting

DOvEE - Diagnosing Ovarian & Endometrial Cancer Early (DOvEE)

Ovarian Neoplasms

Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation | Endometrioid Stromal Sarcoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Ovarian Endometrioid Adenocarcinoma | Endometrial Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | Endometrial Low Grade Endometrioid... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

Recurrent Endometrial Carcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Advanced Endometrial Carcinoma | Metastatic Endometrial Carcinoma

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Endometrial Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Recurrent Endometrial Endometrioid Adenocarcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Metastatic Endometrial Endometrioid Adenocarcinoma

United States
GOG Foundation
Novartis Pharmaceuticals

Active, not recruiting

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

Advanced, Persistent, or Recurrent Endometrial Cancer

United States
Women and Infants Hospital of Rhode Island

Active, not recruiting

Stopping Heavy Periods Project (SHiPP)

Abnormal Uterine Bleeding | Abnormal Uterine Bleeding, Ovulatory Dysfunction | Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Endometrial Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Completed

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Metastatic Endometrioid Adenocarcinoma

United States
Elucida Oncology

Recruiting

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Ovarian Diseases | Ovarian Neoplasms | Ovarian Cancer | Ovarian Epithelial Cancer | Fallopian Tube Cancer | Endometrial Neoplasms | Endometrial Cancer | Endometrial Clear Cell Adenocarcinoma | Ovarian Carcinoma | Endometrial Adenocarcinoma | Peritoneal Cancer | Endometrioid Adenocarcinoma | Ovarian Adenocarcinoma | Ovarian Serous Adenocarcinoma and other conditions

United States
AEterna Zentaris

Completed

Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer (ZoptEC)

Endometrial Cancer

United States, Spain, Canada, Ireland, Norway, Austria, Denmark, Israel, United Kingdom, Belgium, Finland, Romania, Czechia, Italy, Poland, Germany, Netherlands, Belarus, Bosnia and Herzegovina, Bulgaria, Russian Federation, Ukraine
Cancer Trials Ireland

Active, not recruiting

Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study

Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Serous Ovarian Tumor | Endometrioid Carcinoma Ovary

Ireland
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma

United States, Canada
R-Pharm

Terminated

A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer (IXAMPLE2)

Endometrial Cancer

Brazil, Czech Republic, Italy, Mexico, Russian Federation, Sweden, United Kingdom, United States, Spain, Canada, Denmark, France, Peru, Belgium, Hungary, Norway, Argentina, Australia, Greece
University of Florida
National Institute on Aging (NIA)

Recruiting

De-Implementing Fall Prevention Alarms in Hospitals

Mentoring | Accidental Fall | Hospital Acquired Condition | Patient Safety | Clinical Alarms

United States

Clinical Trials on Endometrial Safety in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations